We deliver GMP-aligned, process-driven engineering design solutions dedicated to full-scale mRNA vaccine manufacturing facilities, covering clinical pilot workshops and commercial mass-production plants. Our integrated design scope encompasses regulatory-compliant master zoning, RNase-free cleanroom engineering, specialized low-humidity utility systems, closed process workflow layout, LNP formulation suite optimization and full validation framework deployment. Tailored to address mRNA’s inherent vulnerability to degradation, RNase contamination and LNP particle heterogeneity, our facility design fully adapts to end-to-end production workflows including pDNA amplification, IVT transcription, mRNA purification, LNP microfluidic encapsulation, sterile formulation and cold-chain storage, building inspection-ready infrastructure for global vaccine registration and large-scale commercial supply.
Our facility engineering is anchored on the core philosophies ofhierarchical RNase risk isolation, low-shear process layout, low-humidity environmental control and closed aseptic workflow management. We implement independent pressure cascade zoning and unidirectional personnel/material flow to achieve complete segregation between plasmid preparation, naked mRNA processing and LNP formulation areas, eliminating cross-contamination and RNase intrusion risks. Optimized cleanroom humidity and temperature stabilization systems suppress nucleic acid hydrolysis, while process-centric equipment layout minimizes fluid transfer distance and shear-induced product damage. Modular and expandable structural design supports phased capacity scaling and multi-product flexible production for iterative mRNA vaccine pipelines.
All design criteria, construction specifications and environmental control logic fully comply with FDA mRNA manufacturing guidelines, EMA Annex 1, ICH Q8/Q9/Q10, PIC/S and ISPE biopharmaceutical standards. We embed full lifecycle data integrity architecture compliant with 21 CFR Part 11, enabling immutable traceability of cleanroom environment parameters, process utility status and full batch production records. Every zoning strategy, material specification and contamination control measure is pre-validated for nucleic acid-specific production requirements, ensuring sustained audit readiness for international regulatory inspections and cross-border vaccine market authorization.
We provide end-to-end facility engineering services covering pre-project feasibility study, regulatory gap analysis, conceptual & detailed design, cleanroom and utility system engineering, construction technical guidance, commissioning and full qualification dossier delivery. Our mRNA-specific design methodology eliminates conventional facility-process mismatches, reduces project rework risks and shortens plant validation cycles. Clients obtain highly stable, compliant and future-proof mRNA manufacturing environments to ensure consistent vaccine critical quality attributes, accelerate clinical and commercial launch schedules, and consolidate competitive advantages in the global nucleic acid vaccine industry.
